Abstract
EGFR mutant NSCLC comprises the largest molecular subgroup in NSCLC, with remarkable responses to targeted therapy. However a third of the patients do not respond, and among the responders there exists a heterogeneity in response. A better understanding is still needed of the various attributes of the EGFR mutation itself, apart from the widely studied primary resistance mechanisms. Variant Allele frequency (VAF) which is influenced by tumor proportion, and copy number alteration of the gene is an important attribute and a possible predictor of outcome and response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
